McGregor A, McKay RR, Braun DA, et al. - In this multicenter phase II trial, researchers assessed atezolizumab combined with bevacizumab in individuals with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. Sixty persons received at least one dose of either study agent; the majority (65%) were treatment naïve. In individuals with variant histology RCC or RCC with ≥ 20% sarcomatoid differentiation, atezolizumab and bevacizumab showed safety and lead to objective responses. Moreover, this regimen licenses further investigation in cases with rare RCC, especially those with PD-L1–positive tumors.